CD19-CAR T-cell therapy induces deep tissue depletion of B cells

Objectives CD19-targeting chimeric antigen receptor (CAR) T-cell therapy can induce long-term drug-free remission in patients with autoimmune diseases (AIDs). The efficacy of CD19-CAR T-cell therapy is presumably based on deep tissue depletion of B cells; however, such effect has not been proven in humans in vivo. Methods Sequential ultrasound-guided inguinal lymph node biopsies were performed at baseline and after CD19-CAR T-cell therapy in patients with AIDs. Results were compared with lymph node biopsies from rituximab (RTX)-treated AID patients with absence of peripheral B cells. Conventional and immunohistochemistry staining were performed on lymph node tissue to assess architecture as well the number of…

• EC
  European Commission

  Awards: 853508, CRC1181
• FE
  Friedrich-Alexander-Universität Erlangen-Nürnberg
• DF
  Deutsche Forschungsgemeinschaft

  Awards: 261193037, 493624887, CRC1181, FOR2886, RA 2506/4-1, RA 2506/6-1, CRC1483, RA 2506/4-2, FOR2886 PANDORA, RA 2506/7-1, 405969122, 442419336, 493624887 (Clinician Scientist Program NOTICE)
• BF
  Bundesministerium für Bildung und Forschung

  Award: CRC1181
• SS
  Staedtler Stiftung

  Award: CRC1181
• L
  Leibniz-Gemeinschaft